Kerstin Gorlich

Hannover, NI, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications

XPO1-dependency of DEK::NUP214 leukemia.

XPO1-dependency of DEK::NUP214 leukemia.

Journal: Leukemia
Published: July 12, 2024

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia.

Journal: Annals of hematology
Published: March 10, 2020

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia.

Journal: Haematologica
Published: September 09, 2019

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

Journal: Leukemia
Published: December 11, 2018

Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening.

Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening.

Journal: Current cancer drug targets
Published: April 04, 2016

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.

Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.

Journal: Leukemia
Published: July 21, 2015

Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.

Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling.

Journal: Leukemia
Published: August 21, 2013

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.

Journal: Blood
Published: August 20, 2013

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.

Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes.

Journal: Blood
Published: March 06, 2012

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

ID1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia.

Journal: British journal of haematology
Published: December 28, 2011
Showing 1-10 of 10

Last Updated: 09/26/2026